drugset / Trial / NCT01718509

SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder

NCT01718509

Phase 3 Completed 390 enrolled Shire
RandomizedParallel-groupDouble-blindTreatment

Summary

The primary objective of the study is to demonstrate the efficacy of SPD489 compared with placebo in adults (18 55 years of age inclusive) with moderate to severe Binge Eating Disorder at Visit 8 (Weeks 11 and 12) as measured by the number of binge days (defined as days during which at least 1 binge episode occurs) per week as assessed by clinical interview based on subject diary

Timeline

Start
2012-11-26
Primary completion
2013-09-20
Completion
2013-09-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Lisdexamfetamine Other / unclassified 50 mg Oral
Subject Lisdexamfetamine Other / unclassified 70 mg Oral

Indications